March 25, 2020 / 1:10 PM / in 5 days

BRIEF-Eloxx Pharmaceuticals Provides Update On The Impact Of Novel Coronavirus On Phase 2 Clinical Trials In Cystic Fibrosis

March 25 (Reuters) - Eloxx Pharmaceuticals Inc:

* ELOXX PHARMACEUTICALS PROVIDES UPDATE ON THE IMPACT OF NOVEL CORONAVIRUS (COVID-19) ON PHASE 2 CLINICAL TRIALS IN CYSTIC FIBROSIS

* ELOXX PHARMACEUTICALS INC - ENROLLMENT IN PHASE 2 CYSTIC FIBROSIS TRIALS HAS BEEN PAUSED TEMPORARILY IN RESPONSE TO COVID-19 PANDEMIC

* ELOXX PHARMA - COMMITTED TO COMPLETING ENROLLMENT IN PHASE 2 PROOF OF CONCEPT CLINICAL TRIAL PROGRAM & REPORTING TOP LINE DATA AS SOON AS FEASIBLE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below